Novo Nordisk Gains CHMP Positive Opinion for Wegovy 7.2 mg Single-Dose Pen Ahead of Q3 2026 EU Launch

A CHMP positive opinion for Novo Nordisk's Wegovy 7.2 mg in a single-dose pen format signals that EU marketing authorisation is imminent, and with a Q3 2026 launch target, the device-drug combination manufacturing and regulatory compliance timeline is already in motion. For QA directors and regulatory affairs leads, the convergence of CMC requirements, device validation, and EU MDR obligations on a combination product of this scale warrants close attention.

The opinion, adopted by the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency, covers once-weekly injectable semaglutide 7.2 mg delivered via a single-dose pen. The 7.2 mg dose is not new to the EU market, it is currently available as three separate 2.4 mg injections, but the single-dose pen represents a distinct device configuration requiring its own device validation package and, where applicable, a notified body opinion under EU MDR before the combination product can be placed on the market.

Efficacy data from the 72-week STEP UP phase 3 trial underpinning the submission showed 20.7% mean weight loss in approximately 1,400 adults with obesity, with roughly one in three participants achieving 25% or greater weight loss. In the STEP UP T2D trial, participants with obesity and type 2 diabetes achieved 14.1% mean weight loss. The safety and tolerability profile was consistent with prior semaglutide trials at lower doses.

The single-dose pen format is already approved in the US, where it launched as Wegovy HD, and in the UK, giving Novo Nordisk a reference base for device performance data. For EU submissions, however, the combination product pathway requires alignment between the medicinal product dossier and the device constituent file, a process that plant heads and regulatory leads managing similar programmes will recognise as a parallel-track workstream rather than a sequential one.

Process validation documentation for the new device configuration, including container closure integrity and extractables and leachables data specific to the single-dose pen, will form part of the CMC package already reviewed by CHMP. Any post-approval changes to the device constituent will trigger variation procedures under 21 CFR Part 211 equivalents in the EU framework, adding a layer of change-control discipline that QA teams should factor into lifecycle management planning.

With formal European Commission approval expected to follow the CHMP opinion within the standard 67-day decision window, Novo Nordisk's Q3 2026 EU launch timeline leaves a narrow margin for resolving any outstanding manufacturing or device compliance queries before commercial supply begins.

Source: Novo Nordisk A/S via GlobeNewswire, 22 May 2026.